Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,951 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

NCT01695941

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +12 more
Locations
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, United States
  • Montefiore Medical Center-Einstein Campus The Bronx, New York, United States
  • Montefiore Medical Center - Moses Campus The Bronx, New York, United States
  • Fox Chase Cancer Center Philadelphia, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

NCT02180711

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Research Site Tucson, Arizona, United States
  • Research Site Downey, California, United States
  • Research Site Duarte, California, United States
  • Research Site Fountain Valley, California, United States
View all 29 locations
View Trial Details
Active, Not Recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

NCT06169215

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • UCI Health Laguna Hills Laguna Hills, California, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
View all 27 locations
View Trial Details
Active, Not Recruiting

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

NCT04623541

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +17 more
Locations
  • O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of California Davis Medical Center Sacramento California City, California, United States
  • City of Hope National Medical Center Duarte, California, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
View all 81 locations
View Trial Details
Active, Not Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +16 more
Locations
  • The University of Arizona Cancer Center - North Campus /ID# 242219 Tucson, Arizona, United States
  • Yale University School of Medicine /ID# 242089 New Haven, Connecticut, United States
  • Christiana Care Health Service /ID# 242301 Newark, Delaware, United States
  • Tampa General Hospital /ID# 246748 Tampa, Florida, United States
View all 76 locations
View Trial Details
Active, Not Recruiting

Lenalidomide Maintenance in Plasma Cell Myeloma

NCT02538198

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Memorial Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States
  • Memorial Sloan Kettering Westchester Harrison, New York, United States
View Trial Details
Active, Not Recruiting

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

NCT04542824

Conditions
Chronic Disease, Diffuse Large B Cell Lymphoma, Disease Attributes, +25 more
Locations
  • Tohoku University Hoaspital Sendai, Miyagi, Japan
  • Aichi Cancer Center Hospital Aichi, Japan
  • NHO Nagoya Medical Center Aichi, Japan
  • National Cancer Center Hospital East Chiba, Japan
View all 15 locations
View Trial Details

Related conditions